Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 3/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28176483 | 0.82 | HTT (0.37) | HTTCA2ICMTSIRT1GAA | |
| SCHEMBL339508 | 0.82 | P2RX7 (0.44) | ICMTGAANPSR1ALDH1A1HSD17B10 | |
| SCHEMBL1257814 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2NPSR1ALDH1A1HSD17B10 | |
| SCHEMBL1257818 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2GAANPSR1ALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL14167164 | 0.80 | P2RX7 (0.43) | ICMTGAANPSR1ALDH1A1HSD17B10 | |
| SCHEMBL14294930 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL13343478 | 0.79 | HTT (0.42) | HTTCA2ICMTSIRT1NPSR1 | |
| Ammonia Solution, Strong SCHEMBL28714250 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAALOX15HSD17B10 | |
| SCHEMBL31484258 | 0.77 | GRIN2D (0.33) | HTTCA2SMN1; SMN2ICMTSIRT1 | |
| SCHEMBL11921702 | 0.75 | PPARG (0.36) | HTTSMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | claimed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | HTT 2709/4885CA2 467/4885SMN1; SMN2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.